Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease

Interstitial lung disease (ILD) induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a rare but fatal complication of TKI treatment. Transfer to chemotherapy or continuation with TKI of reduced dose are alternative treatment strategi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Qing, Chen, Liang-an
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2011
Materias:
Published: September 2011
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220897/
https://www.ncbi.nlm.nih.gov/pubmed/22114570
http://dx.doi.org/10.1159/000332195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220897/
https://www.ncbi.nlm.nih.gov/pubmed/22114570
http://dx.doi.org/10.1159/000332195

Ejemplares similares